Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to -$3.0 million.

  • Harmony Biosciences Holdings' Cash from Financing Activities fell 15497.87% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.8 million, marking a year-over-year increase of 8579.59%. This contributed to the annual value of -$11.0 million for FY2024, which is 8958.24% up from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Cash from Financing Activities of -$3.0 million as of Q3 2025, which was down 15497.87% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Cash from Financing Activities ranged from a high of $7.1 million in Q4 2021 and a low of -$55.1 million during Q3 2023
  • Its 5-year average for Cash from Financing Activities is -$5.7 million, with a median of -$339000.0 in 2023.
  • In the last 5 years, Harmony Biosciences Holdings' Cash from Financing Activities surged by 1142500.0% in 2022 and then plummeted by 278775.61% in 2023.
  • Harmony Biosciences Holdings' Cash from Financing Activities (Quarter) stood at $7.1 million in 2021, then tumbled by 62.42% to $2.7 million in 2022, then tumbled by 2113.66% to -$53.5 million in 2023, then soared by 94.88% to -$2.7 million in 2024, then decreased by 9.3% to -$3.0 million in 2025.
  • Its Cash from Financing Activities stands at -$3.0 million for Q3 2025, versus -$2.7 million for Q2 2025 and -$352000.0 for Q1 2025.